ArticleCrohn's & colitis 3602026

A real-world observational study of second-line anti-TNFα treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic.

Chiahung Chou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.